Natixis Advisors LLC Boosts Stock Position in Alkermes plc (NASDAQ:ALKS)

Natixis Advisors LLC boosted its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 36.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 49,922 shares of the company's stock after purchasing an additional 13,432 shares during the quarter. Natixis Advisors LLC's holdings in Alkermes were worth $1,436,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new position in shares of Alkermes during the 4th quarter worth about $25,000. EverSource Wealth Advisors LLC raised its stake in Alkermes by 106.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock worth $47,000 after buying an additional 842 shares during the period. Blue Trust Inc. raised its stake in Alkermes by 2,231.5% during the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company's stock worth $49,000 after buying an additional 1,629 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Alkermes by 558.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company's stock worth $85,000 after acquiring an additional 2,502 shares in the last quarter. Finally, Cornerstone Investment Partners LLC bought a new stake in shares of Alkermes during the fourth quarter valued at approximately $203,000. 95.21% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the sale, the executive vice president now directly owns 57,875 shares in the company, valued at $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.89% of the company's stock.

Remove Ads

Analysts Set New Price Targets

ALKS has been the subject of several research reports. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a research report on Thursday. The Goldman Sachs Group raised their price objective on shares of Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Royal Bank of Canada began coverage on shares of Alkermes in a research report on Thursday, March 13th. They set a "sector perform" rating and a $40.00 target price for the company. HC Wainwright reaffirmed a "neutral" rating and issued a $46.00 price target on shares of Alkermes in a research report on Thursday, February 13th. Finally, UBS Group upgraded Alkermes from a "sell" rating to a "neutral" rating and lifted their price target for the company from $21.00 to $38.00 in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $39.38.

Alkermes Stock Down 1.0 %

Alkermes stock traded down $0.32 during mid-day trading on Friday, reaching $33.21. 922,403 shares of the company's stock were exchanged, compared to its average volume of 1,751,921. The business's fifty day simple moving average is $33.45 and its 200 day simple moving average is $30.29. Alkermes plc has a one year low of $22.90 and a one year high of $36.45. The firm has a market capitalization of $5.40 billion, a PE ratio of 15.30, a P/E/G ratio of 2.20 and a beta of 0.62.

Alkermes (NASDAQ:ALKS - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. On average, sell-side analysts forecast that Alkermes plc will post 1.31 earnings per share for the current year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.